Jazz Pharmaceuticals plc (JAZZ) Company Profile & Statistics

Jazz Pharmaceuticals plc
JAZZ
(Nasdaq - US)
Closed
125.17
+5.93 (+4.97%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
121.99
High
125.65
Low
120.15

About Jazz Pharmaceuticals plc

CEO

Bruce C. Cozadd

Headquarters

fifth floor, waterloo exchange, waterloo road

dublin, l2 d04 e5w7, ireland

Auditor

KPMG

Employees

2,800

Share Holders

889

Website

www.jazzpharma.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.

Jazz Pharmaceuticals plc Statistics

Valuation Measures

Market Capitalization ²	7.57B
Enterprise Value	11.46B
Enterprise Value/EBITDA (ttm)	8.82
Price to Earnings Ratio (ttm)	6.91
Price to Book (mrq)	1.73
Price to Sales (ttm)	1.77
Price to Cash (ytd)	4.20

Profitability

Gross Margin (ttm)	89.38%
Operating Margin (ttm)	28.19%
Profit Margin (ttm)	11.75%
Return on Equity (ttm)	29.30%
Return on Invested Capital (ttm)	4.90%
Return on Assets (ttm)	9.72%

Income Statement

Revenue (ttm)	3.99B
Revenue Per Share (ttm)	66.04
Gross Profit (ttm)	3.57B
EBITDA (ttm)³	1.30B
Net Income Avi to Common (ttm)	488.04M
Diluted EPS (ttm)	7.10

Share Statistics

Beta (5Y Monthly)	0.57
52-Week Change	3.75%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	60.45M
Dividend Yield	0.00%
Float ⁴	57.92M
% Held by Insiders	4.20%
% Held by Institutions	89.14%

Balance Sheet

Total Cash (mrq)	2.62B
Total Cash Per Share (mrq)	43.31
Total Debt (mrq)	6.11B
Total Debt/Equity (mrq)	146.53%
Current Ratio (mrq)	4.26%
Quick Ratio (mrq)	3.74%
Book Value Per Share (mrq)	69.01

Cash Flow

Operating Cash Flow Per Share (ytd)	15.79
Free Cash Flow (ytd)	972.54M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Jazz Pharmaceuticals plc

Trade With A Regulated Broker